FASN and colorectal carcinoma: Upregulation of lipogenic enzymes is commonly observed in patients with aggressive metastatic CRC, and targeting these enzymes, particularly FASN, a key element in the de novo biosynthesis of long-chain fatty acids, presents a viable therapeutic option.